Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2 participants
OBSERVATIONAL
2020-11-09
2022-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
Contrast agents play a key role in diagnosing and managing numerous diseases. Ferumoxytol has been used to image a variety of pathologies and organs, including tumors and inflammation in the brain, liver, pancreas, and prostate. In addition to the different magnetic relaxation properties described above, Ferumoxytol has a higher molecular weight and prolonged blood pool period compared to typical gadolinium-based agents, facilitating imaging vasculature prior to the contrast agent leaking into the extravascular tissue. This has been exploited at higher field strengths and may be particularly advantageous for low field imaging that requires longer scan times. Ferumoxytol iron particles are taken up through the reticuloendothelial system and added to physiologic iron stores, rather than being excreted through the kidneys, resulting in increased plasma half-life while also avoiding concerns related to impaired renal function that sometimes arise with other contrast agents.
The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
Standard images of different types are obtained on the Hyperfine device at the push of a button on an attached touch pad. Imaging protocols include those for anatomical depiction such as balance steady-state free precession (bSFFP), T1-weighted (T1W) gradient echo (GRE), and fast low-angle shot (FLASH) as well as imaging methods focused on the detection of pathology and tissue damage such as diffusion-weighted imaging (DWI), fluid attenuated inversion recovery (FLAIR), and T2-weighted (T2W) fast spin echo (FSE). However, it is not known if existing contrast agents can provide effective contrast in the Hyperfine low-field MRI.
Thus, the primary purpose of this study is to evaluate the efficacy of Ferumoxytol as a contrast agent in low-field MRI scanners. Patients who are already receiving Ferumoxytol as a treatment for iron deficiency anemia will be scanned before and after Ferumoxytol infusion. Degree of contrast enhancement in intravascular and extravascular compartments including the cerebral vasculature and the brain parenchyma will be the primary end-point for the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients prescribed Ferumoxytol for iron deficiency anemia
Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
Hyperfine Portable MRI
The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyperfine Portable MRI
The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prescribed Ferumoxytol for iron deficiency anemia
* Informed consent obtained from patient or a legally authorized representative
Exclusion Criteria
* Electrical implants such as cardiac pacemakers or perfusion pumps
* Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts or heart valves with steel parts, metal fragments, shrapnel, tattoos near the eye, steel implants, or other irremovable ferromagnetic objects
* History of uncontrolled seizures
* Claustrophobia
* Weight greater than or equal to 400 lbs (181.4 kg)
2. Pregnancy
3. Inability or suspected inability to comply with the study procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joel M. Stein, MD, PhD
Assistant Professor of Radiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
842634
Identifier Type: -
Identifier Source: org_study_id